Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Histological improvement (continuous) · inactive EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
Corticosteroids leads to higher histological improvement (dichotomous) compared with placebo (high certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
Corticosteroids showed no clear difference in endoscopic improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · inactive EoE patients
It is very uncertain whether corticosteroids changes clinical improvement (dichotomous) compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (continuous) · inactive EoE patients
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.4 [1.23, 1.6]
41 studies · 41 participants
Very low
OR 1.7 [1.38, 2.09]
17 studies · 17 participants
Low
OR 1.22 [1.03, 1.45]
24 studies · 24 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine probably leads to lower clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review